
Recursion Pharma shares rise 4% after FDA aligns on Phase 3 trial design for AI-driven drug REC-4881.
Recursion Pharmaceuticals' stock rose 3.86% to $2.83 following FDA alignment on the Phase 3 trial design for REC-4881, a treatment for familial adenomatous polyposis, a disease with no approved therapies. The FDA accepted a primary endpoint that coul...



